Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation

Rafael Holdings, Inc. (RFL) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/20/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/19/2021 GN Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference
01/19/2021 8-K Quarterly results
01/14/2021 3 Form 3 - Initial statement of beneficial ownership of securities:
01/13/2021 GN Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
01/07/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/07/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/07/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/07/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/15/2020 10-Q Quarterly Report for the period ended October 31, 2020
12/15/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports First Quarter Fiscal Year 2021 Results"
12/15/2020 GN UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
12/15/2020 GN Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML)
12/11/2020 8-K Unregistered Sales of Equity Securities
12/01/2020 GN Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue
11/23/2020 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/10/2020 GN Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer
10/29/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2020 Results"
10/29/2020 10-K Annual Report for the period ended July 31, 2020
10/29/2020 GN FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma
10/20/2020 GN A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals' Lead Compound CPI-613®? (devimistat) for Patients With Pancreatic Cancer in Japan
09/25/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/01/2020 8-K Other Events
09/01/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentations"
08/06/2020 GN Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®? (devimistat) for Patients with Metastatic Pancreatic Cancer
07/21/2020 GN Rafael Pharmaceuticals Crosses Midpoint of Enrollment to First Interim Analysis in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
06/09/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Third Quarter Fiscal Year 2020 Results"
06/09/2020 10-Q Quarterly Report for the period ended April 30, 2020
05/26/2020 GN Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
05/07/2020 GN Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models
05/05/2020 GN Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer
04/28/2020 GN MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals' Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt's Lymphoma/Leukemia
04/23/2020 GN Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
04/22/2020 4 JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Disposed of 32,711 shares @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy